Sign in

    Dennis Hulme

    Research Analyst at Taylor Collison

    Dr Dennis Hulme serves as a Biotech and Healthcare Analyst at Taylor Collison Limited, where he specializes in equities research covering leading Australian life sciences and healthcare companies. Since joining Taylor Collison in 2019 following a five-year tenure as a biotech analyst at global research house Edison, Dr Hulme has initiated coverage on firms such as SomnoMed, Immutep, and Nova Eye Medical, providing in-depth investment analysis and speculative recommendations. He is recognized for detailed valuation work and fundamental analysis across the biotech sector, although public sources do not disclose specific performance metrics or formal analyst rankings. Dr Hulme holds a Doctorate and a BSc (Hons) in Economics, and actively contributes research certified to comply with Australian regulatory standards for investment advice.

    Dennis Hulme's questions to TLPPF leadership

    Dennis Hulme's questions to TLPPF leadership • Q3 2023

    Question

    Asked about the possibility of adding more treatment cycles to the ProstACT GLOBAL trial given the favorable toxicity profile, and inquired about the timeline for results from the CUPID trial and the nature of the treatment in its final cohort.

    Answer

    The company does not plan to change the two-dose regimen for ProstACT GLOBAL, citing the commercial and clinical advantages of a short treatment course. Results from the CUPID trial's final cohort, which is currently receiving an imaging agent for dosimetry purposes (not the therapeutic alpha agent), are expected early next year.

    Ask Fintool Equity Research AI